Micronized palmitoylethanolamide/trans-polydatin treatment of endometriosis-related pain: a meta-analysis

Ann Ist Super Sanita. 2017 Apr-Jun;53(2):125-134. doi: 10.4415/ANN_17_02_08.

Abstract

Aim: To demonstrate clinical effectiveness of micronized palmitoylethanolamide-trans-polydatin combination in reducing endometriotic chronic pelvic pain. Other endometriotic-pains were also assessed.

Methods: Systematic reviews of PubMed, SCIELO, Scopus, and AJOL. Randomized trials and observational studies reporting a visual analogue scale for pain or similar in endometriotic patients were reviewed. A mean improvement of visual analogue scale (or visual analogue scale-like) scores at enrollment and at a three-month follow-up was assessed and interpreted clinically.

Results: Four studies of poor quality were available. In a heterogeneous sample of endometriotic patients with pain, the administration of micronized palmitoylethanolamide/trans-polydatin (400 mg/40 mg) twice a day for three months provided a clinically relevant improvement of chronic pelvic pain and dysmenorrhea while improving deep dyspareunia to a limited degree. No clinically relevant improvement was found for dyschezia.

Conclusion: More studies are warranted for assessing the drugs-related efficacy.

Publication types

  • Meta-Analysis
  • Review

MeSH terms

  • Amides
  • Drug Combinations
  • Endometriosis / complications*
  • Endometriosis / drug therapy*
  • Ethanolamines / therapeutic use*
  • Female
  • Glucosides / therapeutic use*
  • Humans
  • Pain / drug therapy*
  • Pain / etiology*
  • Pain Management
  • Palmitic Acids / therapeutic use*
  • Stilbenes / therapeutic use*

Substances

  • Amides
  • Drug Combinations
  • Ethanolamines
  • Glucosides
  • Palmitic Acids
  • Stilbenes
  • palmidrol
  • polydatin